Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55)

Immunology

Volumn 98, Issue 2, 1999, Pages 303-311

  Qian, Y M ^a   Haino, M ^b   Kelly, K ^b   Song, W C ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CD97 ANTIGEN; COMPLEMENTARY DNA; DECAY ACCELERATING FACTOR; EPIDERMAL GROWTH FACTOR; GREEN FLUORESCENT PROTEIN; HLA ANTIGEN; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL ADHESION; CELL MEMBRANE; ERYTHROCYTE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KIDNEY CELL; KNOCKOUT MOUSE; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN TARGETING; SPLEEN CELL; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD; ANTIGENS, CD55; BASE SEQUENCE; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL ADHESION; CELL LINE; CELL MEMBRANE; CELLS, CULTURED; ERYTHROCYTES; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; SEQUENCE ALIGNMENT; SPECIES SPECIFICITY; SPLEEN;

EID: 0032884233     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.1999.00859.x     Document Type: Article

References (26)

1. 1 . EICHLER W., AUST G. & HAMANN D. (1994) Characterization of an early activation-dependent antigen on lymphocytes defined by the monoclonal antibody BL-Ac (F2). Scand J Immunol 39, 111.
2. 2. HAMANN J., EICHLER W., HAMANN D. et al. (1995) Expression cloning and chromosomal mapping of the leukocyte activation antigen CD97, a new seven-span transmembrane molecule of the secretin receptor superfamily with an unusual extracellular domain. J Immunol 155, 1942.
3. 3. EICHLER W., HAMANN J. & AUST G. (1997) Expression characteristics of the human CD97 antigen. Tissue Antigens 50, 429.
4. 4. GRAY J.X., HAINO M., ROTH M.J. et al. (1996) CD97 is a processed, seven-transmembrane, heterodimeric receptor associated with inflammation. J Immunol 157, 5438.
5. 5. DAVIS C.G. (1990) The many faces of epidermal growth factor repeats. New Biol 2, 410.
6. 6. D'SOUZA S.E., GINSBERG M.H. & PLOW E.F. (1991) Arginylglycyl-aspartic acid (RGD): a cell adhesion motif. Trends Biochem Sci 16, 246.
7. 7. HAMANN J., VOGEL. B., VAN SCHIJINDEL G.M.W. & VAN LIER R.A.W. (1996) The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J Exp Med 184, 1185.
8. 8. HAMANN J., STORTELERS C., KISS-TOTH E., VOGEI B., EICHLER W. & VAN LIER R.A.W. (1998) Characterization of the CD55 (DAF)-binding site on the seven-span transmembrane receptor CD97. Eur J Immunol 28, 1701.
9. 9. MCKNIGHT A.J. & GORDON S. (1998) The EGF-TM7 family: unusual structures at the leukocyte surface. J Leukoc Biol 63, 271.
10. 10. SUN X., FUNK C.D., DENG C., SAHU A., LAMBRIS J.D. & SONG W.-C. (1999) Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. Proc Natl Acad Sci USA 96, 628.
11. 11. LEE C.C. & CASKEY C.T. (1990) Rapid amplification od cDNA ends. In: PCR Protocols, a Guide to Methods and Applications pp. 46. (eds. M. A. Innis, D. H. Gelfand, J. J. Sninsky & T. J. White) Academic Press, NY.
12. 12. KYTE J. & DOOLITTLE R.F. (1982) A simple method for displaying the hydropathic character of a protein. J Mol Biol 157, 105.
13. 13. HANDFORD P.A., MAYHEW M., BARON M., WINSHIP P.R., CAMPBELL I.D. & BROWNLEE G.G. (1991) Key residues involved in calcium-binding motifs in EGF-like domains. Nature 351, 164.
14. 14. SELANDER-SUNNERSHAGEN M.M.M., ULLNER E., PERSSON O., TELEMAN J., STENFLO & DRAKENBERG T. (1992) How an epidermal growth factor (EGF) -like domain binds calcium. J Biol Chem 261, 19642.
15. 15. MCKNIGHT A., MACFARLANE A.J., TURLEY P., DRI L., WILLIS A.G. & GORDON S. (1996) Molecular cloning of F4/80, a murine macrophage-restricted cell surface glycoprotein with homology to the G-protein-linked transmembrane 7 hormone receptor family. J Biol Chem 271, 486.
16. 16. BAUD V., CHISSOE S.L., VIEGAS-PEQUIGNOT E. et al. (1995) EMR1, an unusual member in the family of hormone receptors with seven transmembrane segments. Genomics 26, 334.
17. 17. LUBLIN D. & ATKINSON J.P. (1989) Decay-accelerating factor: biochemistry, molecular biology, and function. Annu Rev Immunol 7, 35.
18. 18. NICHOLSON-WELLER A. & WANG C.E. (1994) Structure and function of decay accelerating factor. J Lab Clin Med 123, 485.
19. 19. SONG W.-C, DENG C., RASZMANN K. et al. (1996) Mouse decay-accelerating factor: selective and tissue-specific induction by estrogen of the gene encoding the glycosylphosphatidylinositol-anchored form. J Immunol 157, 4166.
20. 20. AUST G.W., EICHLER S., LAUE I. et al. (1997) CD97: a dedifferentiation marker in human thyroid carcinomas. Cancer Res 57, 1798.
21. 21. MEDOF M.E., WALTER E.I., RUTGERS J.L., KNOWLES D.M. & NUSSENZWEIG V. (1987) Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med 165, 848.
22. 22. HINDMARSH E.J. & MARKS R.M. (1998) Decay-accelerating factor is a component of subendothelial extracellular matrix in vitro, and is augmented by activation of endothelial protein kinase C. Eur J Immunol 28, 1052.
23. 23. KORETZ K., BRUDERLIEN S., HENNE C, & MOLLER P. (1992) Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas. Br J Cancer 66, 810.
24. 24. BERNET-CAMARD M.-F., COCONNIER M.-H., HUDAULT S. & SERVIN A.L.L. (1995) Differential expression of complement proteins and regulatory decay-accelerating factor in relation to differentiation of cultured human colon adenocarcinoma cell lines. Gut 38, 248.
25. 25. BJORGE L., HAKULINEN J., WAHLSTROM T., MATRE R. & MERI S. (1997) Complement-regulatory proteins in ovarian malignancies. Int J Cancer 70, 14.
26. 26. TERACHI T., STANESCU G., PONTES J.E., MEDOF M.E. & CAULFIELD M. (1991) Coexistence of autologous antibodies and decay-accelerating factor, an inhibitor of complement, on human renal tumor cells. Cancer Res 51, 2521.